TrialSite’s coverage in the past year includes the ongoing research and development associated with France-based MedinCell, the biotech developing several long-acting injectable formulations of ivermectin. They are one of the few commercial entities seeking to develop a product for the market although there are others covered by this media platform. Now the Montpellier-based venture that also develops products for malaria reports that a clinical trial has validated the safety of ivermectin taken daily in oral form, to simulate the continuous release of the active substance by long-acting injection. The company seeks to advance this investigational product as one to prevent infection from SARS-CoV-2 and its mutants for several months. This study follows over 50 clinical trials from around the world, showcasing that the drug within certain dosage amounts is not only safe but also effective. This mounting data, however, is countered by a recalcitrant industry, regulatory and academic-driven resistance to a low cost, generic option targeting COVID-19.
In a recent press release, the company reports they have produced positive safety results. Chief Development O...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).